Shots:

• Aarvik to receive $100M up front, research funding, option fees & is also eligible to receive development and commercial milestones along with royalties
• The collaboration will use ArriVent’s global development expertise with Aarvik’s modular Ab platform to advance novel cancer therapeutics
• Under the terms of collaboration, Aarvik is responsible for the discovery and preclinical development of the novel molecule based on its modular platform that combines multiple target mechanisms while ArriVent will lead the clinical development and commercialization of the drug candidate

Ref: Businesswire | Image: Aarvik